查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1974100

软组织肉瘤市场：依治疗方法、组织学亚型、最终用户和通路－2026-2032年全球预测

Soft Tissue Sarcomas Market by Treatment Type, Histological Subtype, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年软组织肉瘤市场价值为 8.0254 亿美元，预计到 2026 年将成长至 8.8492 亿美元，复合年增长率为 10.14%，到 2032 年将达到 15.7814 亿美元。

主要市场统计数据
基准年 2025 8.0254亿美元
预计年份：2026年 8.8492亿美元
预测年份 2032 1,578,140,​​000 美元
复合年增长率 (%) 10.14%

全面概述了软组织肉瘤的临床复杂性以及影响治疗策略和护理路径的跨学科进展。

软组织肉瘤是一组起源于间叶组织的恶性肿瘤，其组织学类型、解剖位置和治疗反应的多样性给临床医生和医疗保健系统带来了挑战。对于局部病变，治疗方案通常包括手术和放射线治疗的联合应用。然而，在晚期或难治性病例中，从成熟的细胞毒性疗法到前沿的标靶治疗疗法和免疫疗法等全身性治疗发挥着至关重要的作用。儘管近年来临床进展拓展了治疗选择，但诊断、亚型分类和持续疾病控制仍然是亟待解决的临床难题。

免疫肿瘤学、精准诊断和适应性开发范式的创新如何重塑肉瘤治疗的治疗流程和商业模式。

软组织肉瘤的治疗格局正在经历一场变革，这主要得益于免疫肿瘤学、标靶药物和精准诊断领域的创新。查核点抑制剂和过继性细胞疗法正从实验阶段走向针对特定亚型的明确适应症，促使人们重新评估临床试验设计、生物标记开发和联合治疗策略。同时，抑制主要讯号通路和激酶的标靶治疗正在优化治疗顺序，并为分子分型明确的患者群体提供新的治疗选择。

2025年美国关税趋势对肿瘤供应链、筹资策略、临床试验物流及治疗方案取得规划的影响

影响跨境贸易和供应链的政策变化对肿瘤治疗药物的供应、筹资策略和临床运作有重大影响。 2025年美国关税趋势可能导致进口药品原料药、特殊试剂以及某些用于手术和门诊的医疗设备的到岸成本增加。这种情况将促使製造商和医疗系统重新评估其筹资策略，寻找替代供应商，并考虑本地生产和库存缓衝，以降低供应中断的风险。

深度分割分析揭示了治疗方法、组织学异质性、医疗保健环境和通路相互作用以塑造临床和商业策略的机制。

细分市场层面的洞察突显了每种治疗类型、组织类型、最终用户和分销管道的不同需求驱动因素、临床需求和商业化考量。基于治疗类型的分类包括化疗、联合治疗、免疫疗法、放射线治疗、手术和标靶治疗。化疗进一步细分为烷化剂、细胞週期蛋白药物和紫杉烷类药物，而免疫疗法则分为过继性细胞疗法和查核点抑制剂。标靶治疗以单株抗体、mTOR抑制剂和蛋白酪氨酸激酶抑制剂为特征。每种治疗方法都有其独特的研发进度、给药环境和证据要求，这些因素都会影响其应用和健保报销决策。

监管多样性、证据要求和基础设施发展等关键区域观点，影响着世界各地药物的取得和商业化。

区域趋势影响着美洲、欧洲、中东和非洲以及亚太地区的创新采纳、报销框架和临床实践模式，进而塑造製造商和医疗保健系统的战略重点。在美洲，集中的临床研究活动、先进的转诊网络和专科中心促进了新治疗方法的快速引入，而支付方和私人保险公司则日益重视价值证明和基于结果的合约。欧洲、中东和非洲地区的特点是监管环境多样，报销途径各异，因此需要製定有针对性的市场进入策略和区域性证据生成，以支持各国医疗保健系统采纳这些疗法。

生态系统趋势揭示了製药公司、生物技术公司、服务供应商和诊断合作伙伴如何合作推动肉瘤治疗的开发和商业化。

软组织肉瘤领域的竞争格局以大型製药企业、专业生物技术公司、临床研究机构和诊断技术创新公司之间的合作为特征。通常，成熟的製药公司会利用其规模优势来支持后期临床计画和全球商业化，确保处方集被纳入处方并维持稳定的供应。特别是生物技术公司，它们在细胞疗法、新型免疫调节剂和高选择性标靶药物等小众和高风险领域推动创新，并经常与大型公司合作以加速研发和推广。

领导者应采取切实可行的策略重点，整合精准开发、弹性价值炼和支付方合作，以加速提高医疗服务可近性并创造长期价值。

产业领导者应优先考虑将科学研究机会与营运韧性和支付方预期相结合的策略，以最大限度地提高临床影响和商业性成功。首先，从研发早期阶段就投资于强大的诊断和生物标记项目，以实现精准的患者筛选并建立令人信服的卫生经济学论证。其次，设计具有可操作终点的临床试验，这些终点应体现适应性因素和真实世界的临床实践，并促进与监管机构的合作以及与支付方的对话。第三，建构供应链冗余和区域生产方案，以降低关税和物流风险，并确保临床试验和商业供应的连续性。

我们透过严谨的混合调查方法提供检验的策略见解，该方法整合了同行评审的证据、相关人员访谈和迭代检验。

本分析整合了多种调查方法，以确保策略洞察的严谨性和可重复性。二次研究全面回顾了同行评审文献、监管指南、临床试验註册资讯和公共声明，重点关注与软组织肉瘤治疗和诊断相关的最新同行评审临床数据、指南更新和监管路径。一次研究则包括对临床专家、医疗系统领导者、支付方和行业高管进行结构化访谈，检验趋势、阐明营运实际情况并识别全社会尚未满足的需求。

我们策略性地整合临床创新、营运韧性和相关人员参与，以推动病患疗效和就医途径的显着改善。

软组织肉瘤的治疗格局正处于一个转折点，科学进步与不断发展的医疗服务和商业模式在此交会融合。精准诊断和标靶治疗正在重新定义患者群体，而免疫肿瘤学和细胞疗法则拓展了治疗的可能性。此外，供应链韧性和支付方协作等关键营运挑战对于治疗的成功实施也日益重要。透过投资生物标记、设计适应性临床试验、建立策略伙伴关係以及加强供应和准入系统等倡议，整合这些临床和商业性因素的利益相关人员，将更有能力把创新转化为切实的患者获益。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 软组织肉瘤市场依治疗方法

  • 化疗
    • 烷化剂
    • 细胞週期蛋白药物
    • 紫杉烷类药物
  • 联合治疗
  • 免疫疗法
    • 过继性细胞疗法
    • 查核点抑制剂
  • 放射线治疗
  • 外科手术
  • 标靶治疗
    • 单株抗体
    • mTOR抑制剂
    • 蛋白酪氨酸激酶抑制剂

第九章 软组织肉瘤市场（依组织学亚型划分）

  • 纤维肉瘤
  • 平滑肌肉瘤
  • 脂肪肉瘤
  • 恶性週边神经鞘瘤
  • 滑膜肉瘤
  • 未分化多形性肉瘤

第十章 软组织肉瘤市场：依最终使用者划分

  • 门诊手术中心
  • 癌症专科诊所
  • 居家医疗环境
  • 医院

第十一章 软组织肉瘤市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章 软组织肉瘤市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 软组织肉瘤市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 软组织肉瘤市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国软组织肉瘤市场

第十六章：中国软组织肉瘤市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Adaptimmune Therapeutics plc
  • Bayer AG
  • Deciphera Pharmaceuticals, Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Janssen Pharmaceutica NV
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • PharmaMar, SA
Product Code: MRR-5D340F440B83

The Soft Tissue Sarcomas Market was valued at USD 802.54 million in 2025 and is projected to grow to USD 884.92 million in 2026, with a CAGR of 10.14%, reaching USD 1,578.14 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 802.54 million
Estimated Year [2026] USD 884.92 million
Forecast Year [2032] USD 1,578.14 million
CAGR (%) 10.14%

Comprehensive overview of clinical complexity and multidisciplinary advancements shaping therapeutic strategies and care pathways in soft tissue sarcoma management

Soft tissue sarcomas represent a heterogeneous group of malignancies arising from mesenchymal tissues that challenge clinicians and health systems due to their varied histologies, anatomical locations, and therapeutic responses. Treatment pathways routinely integrate surgery and radiation for localized disease, while systemic therapies-spanning established cytotoxic regimens to modern targeted and immune-based approaches-play pivotal roles for advanced and refractory cases. Recent clinical advances have broadened the therapeutic armamentarium, yet diagnosis, subtype classification, and durable disease control remain pressing clinical priorities.

Clinical research now emphasizes precision approaches that align molecular profiles with therapeutic mechanisms, while multidisciplinary care models are increasingly recognized as essential to optimize outcomes. The interplay between evolving treatment modalities and care delivery settings underscores the need for nuanced intelligence to support R&D investment, clinical program design, and care pathway optimization. This executive summary synthesizes the most consequential developments shaping clinical practice, commercial strategy, and access in the soft tissue sarcoma landscape, offering a clear foundation for informed decision-making across stakeholders.

How innovations in immuno-oncology, precision diagnostics, and adaptive development paradigms are reshaping treatment algorithms and commercial models in sarcoma care

The therapeutic landscape for soft tissue sarcomas is undergoing transformative shifts driven by innovations in immuno-oncology, targeted agents, and precision diagnostics. Checkpoint inhibitors and adoptive cell therapies are moving from experimental settings into defined indications for select subtypes, prompting re-evaluation of trial design, biomarker development, and combination strategies. Concurrently, targeted therapies that inhibit key signaling pathways and kinases are refining treatment sequencing and offering new options for molecularly defined patient cohorts.

These clinical advances are accompanied by shifts in development paradigms: adaptive trial designs, tumor-agnostic regulatory pathways for molecularly targeted approaches, and increased emphasis on real-world evidence to demonstrate value beyond randomized controlled trials. Health systems are responding with investment in centralized diagnostic capabilities and multidisciplinary tumor boards to ensure accurate histological and molecular classification. As a result, commercial models must adapt to a landscape where precision diagnostics, specialty channels, and value-based contracting influence uptake and reimbursement, influencing how therapies are developed, launched, and scaled.

Implications of 2025 United States tariff developments on oncology supply chains, procurement strategies, clinical trial logistics, and therapeutic access planning

Policy shifts impacting cross-border trade and supply chains have meaningful implications for therapeutic availability, procurement strategies, and clinical operations in oncology. United States tariff dynamics in 2025 have the potential to increase the landed cost of imported active pharmaceutical ingredients, specialty reagents, and certain medical devices used in surgical and outpatient settings. This context incentivizes manufacturers and health systems to review sourcing strategies, explore alternative suppliers, and consider localized manufacturing or inventory buffering to mitigate supply disruption risks.

Beyond direct cost effects, tariff-driven adjustments can extend lead times and complicate logistics for investigational agents and clinical trial materials, particularly when global supply chains involve multiple jurisdictions. Sponsors and clinical sites are therefore advised to strengthen supply chain visibility, diversify supplier portfolios, and engage proactively with contract manufacturers. Payers and procurement teams may face additional pressure to renegotiate contracts or prioritize therapeutics that demonstrate clear value in constrained procurement environments. In sum, tariff developments in 2025 underscore the strategic importance of resilient sourcing, flexible clinical supply planning, and policy engagement to sustain access to critical therapies and innovations.

Deep segmentation insights revealing how therapeutic modalities, histological heterogeneity, care settings, and distribution pathways interact to shape clinical and commercial strategies

Segment-level insights highlight distinct demand drivers, clinical needs, and commercialization considerations across treatment types, histologies, end users, and distribution channels. Based on treatment type, the spectrum encompasses Chemotherapy, Combination Therapy, Immunotherapy, Radiation Therapy, Surgery, and Targeted Therapy, with Chemotherapy further differentiated into Alkylating Agents, Anthracyclines, and Taxanes, Immunotherapy divided into Adoptive Cell Therapy and Checkpoint Inhibitors, and Targeted Therapy characterized by Monoclonal Antibodies, mTOR Inhibitors, and Tyrosine Kinase Inhibitors. Each modality carries unique development timelines, administration settings, and evidence requirements that influence adoption and reimbursement decisions.

Based on histological subtype, distinct biological behaviors and therapeutic sensitivities are observed across Fibrosarcoma, Leiomyosarcoma, Liposarcoma, Malignant Peripheral Nerve Sheath Tumor, Synovial Sarcoma, and Undifferentiated Pleomorphic Sarcoma, necessitating subtype-specific clinical strategies and targeted research efforts. Based on end user, care is delivered across ambulatory surgical centers, cancer specialty clinics, home care settings, and hospitals, which affects where therapies are administered, how supportive care is coordinated, and which stakeholders influence procurement. Based on distribution channel, medication access and dispensing occur through hospital pharmacies, online pharmacy platforms, and retail pharmacies, shaping patient convenience, adherence potential, and specialty dispensing requirements. Cross-segment interactions-such as the need for intravenous administration constraining distribution to hospital and specialty clinic settings-are central to commercial planning and clinical pathway design.

Critical regional perspectives on regulatory diversity, evidence requirements, and infrastructure readiness shaping access and commercialization across global territories

Regional dynamics influence innovation adoption, reimbursement frameworks, and clinical practice patterns across the Americas, Europe, Middle East & Africa, and Asia-Pacific, shaping strategic priorities for manufacturers and health systems. In the Americas, a concentration of clinical research activity, advanced referral networks, and specialized centers fosters rapid adoption of novel therapies, while payers and private insurers increasingly emphasize value demonstration and outcomes-based contracting. Europe, Middle East & Africa features diverse regulatory landscapes and heterogeneous reimbursement pathways that require targeted market access strategies and regional evidence generation to support adoption across national health systems.

The Asia-Pacific region encompasses a wide range of market maturities; several countries are actively expanding oncology infrastructure, investing in molecular diagnostics, and accelerating clinical trial participation, which presents both opportunities and operational challenges for market entrants. Cross-regional collaboration, harmonization of regulatory expectations, and region-specific evidence packages are critical to optimize launch sequencing and to ensure equitable patient access. Understanding these geographic nuances enables stakeholders to prioritize investments, tailor engagement strategies with payers and providers, and design supply chain approaches that account for regional manufacturing and distribution considerations.

Ecosystem dynamics revealing how pharma, biotech innovators, service providers, and diagnostic partners collaborate to advance sarcoma therapeutics and commercialization

Competitive activity in soft tissue sarcomas is characterized by collaboration between large pharmaceutical companies, specialized biotechnology firms, clinical research organizations, and diagnostic innovators. Broadly, established pharmaceutical organizations continue to support late-stage clinical programs and global commercialization, leveraging scale to secure formulary positioning and supply resilience. Biotechnology entities drive innovation in niche and high-risk areas, particularly in cell-based therapies, novel immune modulators, and highly selective targeted agents, often partnering with larger firms to accelerate development and distribution.

Service providers such as contract research organizations and contract manufacturing organizations play an increasing role in enabling rapid trial execution and scalable production of complex biologics and cell therapies. Diagnostic companies and pathology networks contribute essential capabilities for molecular and histological characterization, supporting precision oncology pathways. Strategic collaborations, licensing arrangements, and selective acquisitions are prevalent as stakeholders seek complementary competencies: proprietary platforms and translational science offered by smaller innovators, and commercialization reach and regulatory expertise provided by larger partners. These dynamics drive a competitive ecosystem where differentiation depends on therapeutic efficacy, companion diagnostics, access strategies, and operational execution.

Actionable strategic priorities for leaders to align precision development, resilient supply chains, and payer engagement to accelerate access and long-term value creation

Industry leaders should prioritize strategies that align scientific opportunity with operational resilience and payer expectations to maximize clinical impact and commercial success. First, invest in robust diagnostic and biomarker programs early in development to enable precise patient selection and to support compelling health economic narratives. Second, design clinical trials with adaptive elements and pragmatic endpoints that reflect real-world practice, facilitating regulatory engagement and payer dialogue. Third, build supply chain redundancy and regional manufacturing options to mitigate tariff-related and logistical risks, ensuring continuity for clinical trials and commercial supply.

Further, cultivate partnerships with specialty care networks and outpatient providers to streamline administration pathways and enhance patient access, while designing distribution strategies that balance hospital-based infusion requirements with emerging home-care capabilities. Finally, proactively engage payers and policy stakeholders to align evidence generation with reimbursement needs, exploring value-based agreements where appropriate to demonstrate outcomes and share risk. Collectively, these actions position organizations to translate scientific advances into durable patient benefit while navigating an increasingly complex commercial environment.

Rigorous mixed-methods research approach integrating peer-reviewed evidence, stakeholder interviews, and iterative triangulation to deliver validated strategic insights

This analysis synthesizes multiple research approaches to ensure a rigorous and reproducible foundation for strategic insights. Secondary research involved a comprehensive review of peer-reviewed literature, regulatory guidance, clinical trial registries, and public policy statements, focusing on the latest peer-reviewed clinical data, guideline updates, and regulatory pathways relevant to soft tissue sarcoma therapy and diagnostics. Primary research incorporated structured interviews with clinical experts, health system leaders, payers, and industry executives to validate trend interpretation, clarify operational realities, and identify unmet needs across care settings.

Data were triangulated across sources to reconcile evidence gaps and to enhance the robustness of conclusions. The methodology emphasized transparency in assumptions, rigorous cross-validation of clinical and operational findings, and iterative expert review to ensure the relevance and accuracy of insights. Limitations and contextual considerations are acknowledged, including variability in regional practices and the evolving nature of clinical evidence; therefore, recommendations prioritize adaptable approaches that can be refined as new data emerge.

Strategic synthesis of clinical innovation, operational resilience, and stakeholder engagement to drive meaningful improvements in patient outcomes and access

The soft tissue sarcoma landscape is at an inflection point where scientific advances are converging with evolving care delivery and commercial models. Precision diagnostics and targeted therapeutics are redefining patient segments, immuno-oncology and cell-based modalities are expanding therapeutic possibilities, and operational imperatives such as supply chain resilience and payer alignment are increasingly central to successful implementation. Stakeholders that integrate these clinical and commercial dimensions-by investing in biomarkers, designing adaptive trials, forging strategic partnerships, and strengthening supply and access mechanisms-will be best positioned to translate innovation into tangible patient benefit.

Looking ahead, continuous engagement with clinicians, payers, and patient communities will be essential to ensure that emerging therapies are introduced in ways that are clinically meaningful, economically sustainable, and operationally feasible. By adopting a proactive, evidence-driven approach, organizations can navigate complexity, seize opportunities for differentiation, and contribute to improved outcomes for patients living with soft tissue sarcomas.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Soft Tissue Sarcomas Market, by Treatment Type

  • 8.1. Chemotherapy
    • 8.1.1. Alkylating Agents
    • 8.1.2. Anthracyclines
    • 8.1.3. Taxanes
  • 8.2. Combination Therapy
  • 8.3. Immunotherapy
    • 8.3.1. Adoptive Cell Therapy
    • 8.3.2. Checkpoint Inhibitors
  • 8.4. Radiation Therapy
  • 8.5. Surgery
  • 8.6. Targeted Therapy
    • 8.6.1. Monoclonal Antibodies
    • 8.6.2. mTOR Inhibitors
    • 8.6.3. Tyrosine Kinase Inhibitors

9. Soft Tissue Sarcomas Market, by Histological Subtype

  • 9.1. Fibrosarcoma
  • 9.2. Leiomyosarcoma
  • 9.3. Liposarcoma
  • 9.4. Malignant Peripheral Nerve Sheath Tumor
  • 9.5. Synovial Sarcoma
  • 9.6. Undifferentiated Pleomorphic Sarcoma

10. Soft Tissue Sarcomas Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Cancer Specialty Clinics
  • 10.3. Home Care Settings
  • 10.4. Hospitals

11. Soft Tissue Sarcomas Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacies

12. Soft Tissue Sarcomas Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Soft Tissue Sarcomas Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Soft Tissue Sarcomas Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Soft Tissue Sarcomas Market

16. China Soft Tissue Sarcomas Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Adaptimmune Therapeutics plc
  • 17.6. Bayer AG
  • 17.7. Deciphera Pharmaceuticals, Inc.
  • 17.8. Eisai Co., Ltd.
  • 17.9. Eli Lilly and Company
  • 17.10. Janssen Pharmaceutica NV
  • 17.11. Merck KGaA
  • 17.12. Novartis AG
  • 17.13. Pfizer Inc.
  • 17.14. PharmaMar, S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SOFT TISSUE SARCOMAS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SOFT TISSUE SARCOMAS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ANTHRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ANTHRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ANTHRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TAXANES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TAXANES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TAXANES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY FIBROSARCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY FIBROSARCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY FIBROSARCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY LEIOMYOSARCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY LEIOMYOSARCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY LEIOMYOSARCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY MALIGNANT PERIPHERAL NERVE SHEATH TUMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY MALIGNANT PERIPHERAL NERVE SHEATH TUMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY MALIGNANT PERIPHERAL NERVE SHEATH TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY SYNOVIAL SARCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY SYNOVIAL SARCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY SYNOVIAL SARCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY UNDIFFERENTIATED PLEOMORPHIC SARCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY UNDIFFERENTIATED PLEOMORPHIC SARCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY UNDIFFERENTIATED PLEOMORPHIC SARCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CANCER SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CANCER SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CANCER SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. GCC SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GCC SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. GCC SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. GCC SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. GCC SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. GCC SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2032 (USD MILLION)
  • TABLE 170. GCC SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. GCC SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. G7 SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. G7 SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. G7 SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. G7 SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 192. G7 SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. G7 SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2032 (USD MILLION)
  • TABLE 194. G7 SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. G7 SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. NATO SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. NATO SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. NATO SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. NATO SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. NATO SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2032 (USD MILLION)
  • TABLE 202. NATO SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. NATO SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)